| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$1,510,000 ) |
| | 2025 | 2023 | SURROZEN OPERATING INC | 171 OYSTER POINT BLVD | SOUTH SAN FRANCISCO | CA | 94080-2024 | SAN MATEO | USA | U01AA028951 | A hepatocyte-specific R-spondin mimetic bispecific fusion protein to stimulate hepatocyte regeneration in patients with acute alcoholic hepatitis | 001 | 4 | NIH | 11/1/2024 | -$505,000 |
| | 2025 | 2022 | SURROZEN OPERATING INC | 171 OYSTER POINT BLVD | SOUTH SAN FRANCISCO | CA | 94080-2024 | SAN MATEO | USA | U01AA028951 | A hepatocyte-specific R-spondin mimetic bispecific fusion protein to stimulate hepatocyte regeneration in patients with acute alcoholic hepatitis | 000 | 3 | NIH | 11/1/2024 | -$1,005,000 |
|
| Issue Date FY: 2024 ( Subtotal = $500,000 ) |
| | 2024 | 2023 | SURROZEN OPERATING INC | 171 OYSTER POINT BLVD | SOUTH SAN FRANCISCO | CA | 94080-2024 | SAN MATEO | USA | U01AA028951 | A hepatocyte-specific R-spondin mimetic bispecific fusion protein to stimulate hepatocyte regeneration in patients with acute alcoholic hepatitis | 002 | 4 | NIH | 6/19/2024 | $0 |
| | 2024 | 2022 | SURROZEN OPERATING INC | 171 OYSTER POINT BLVD | SOUTH SAN FRANCISCO | CA | 94080-2024 | SAN MATEO | USA | U01AA028951 | A hepatocyte-specific R-spondin mimetic bispecific fusion protein to stimulate hepatocyte regeneration in patients with acute alcoholic hepatitis | 001 | 3 | NIH | 12/5/2023 | $500,000 |
|
| Issue Date FY: 2023 ( Subtotal = $505,000 ) |
| | 2023 | 2023 | SURROZEN OPERATING, INC. | 171 OYSTER POINT BLVD | SOUTH SAN FRANCISCO | CA | 94080-2024 | SAN MATEO | USA | U01AA028951 | A hepatocyte-specific R-spondin mimetic bispecific fusion protein to stimulate hepatocyte regeneration in patients with acute alcoholic hepatitis | 000 | 4 | NIH | 9/22/2023 | $505,000 |
|
| Issue Date FY: 2022 ( Subtotal = $505,000 ) |
| | 2022 | 2022 | SURROZEN OPERATING, INC. | 171 OYSTER POINT BLVD | SOUTH SAN FRANCISCO | CA | 94080-1936 | SAN MATEO | USA | U01AA028951 | A hepatocyte-specific R-spondin mimetic bispecific fusion protein to stimulate hepatocyte regeneration in patients with acute alcoholic hepatitis | 001 | 3 | NIH | 9/21/2022 | $505,000 |
|
|
